The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at an unprecedented speed to develop vaccines, treatments, and tests This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. This first part is […]Read More
Shots: The collaboration leverages Adaptive’s immune medicine platform for the identification of virus-neutralizing Abs with Amgen’s proficiency in immunology and novel Abs development Adaptive extends immune medicine platform to discover Abs from recovered COVID-19 patients, which enables the company to identify Abs from survivors of COVID-19 to select those that neutralize SARS-CoV-2 Amgen will leverage […]Read More
Shots: The companies collaborate on mapping the immune system’s response to threats, including the COVID-19 threat The focus of the alliance is to study population-wide immune responses to the COVID-19 with their findings to be publicly available via an open data portal. Following the study of immune responses, the companies expected to provide unique insight […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
